Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-002 + lenvatinib
- Development stage
- Unknown
- Lead developer
- ImmuneOncia Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IMC-002 + lenvatinib is an investigational combination therapy for advanced hepatocellular carcinoma (HCC), currently in Phase 1b clinical development. IMC-002 is a next-generation, fully human IgG4 monoclonal antibody targeting the CD47-SIRPα pathway to restore macrophage-mediated phagocytosis of tumor cells, while lenvatinib is an oral small molecule multi-kinase inhibitor approved as Lenvima, acting on targets such as VEGFR, FGFR, PDGFRα, KIT, and RET. IMC-002 is designed to minimize binding to normal cells and avoid hematologic toxicity. The combination is being evaluated as a second-line option for HCC patients refractory to prior treatment.
- Other names
- IMC-002 + lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)CD47 (Cluster of Differentiation 47)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SIRPA (Signal-regulatory protein alpha)FGFR3 (Fibroblast growth factor receptor 3)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on IMC-002 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-002 + lenvatinib.